Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Switching from finasteride to dutasteride and back to finasteride led to gynecomastia and fatigue, likely due to hormonal imbalances. Suggested treatments include Tamoxifen, Raloxifene, or low-dose Anastrozole, with a recommendation to test testosterone and estradiol levels.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

A 17-year-old is experiencing diffuse thinning, dandruff, body hair shedding, and other symptoms, possibly linked to seborrheic dermatitis or telogen effluvium. They are using ketoconazole shampoo and considering blood tests to check for thyroid issues or deficiencies.

The conversation is about the effectiveness of hair loss treatments, specifically finasteride and dutasteride, in different populations. Some users believe that the results of Japanese studies may not be relevant to Caucasian men, especially young ones, and that East Asians may respond better to these treatments. Others argue that clinical studies should be the basis for decision-making, while acknowledging that individual responses to medications can vary.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

The user is experiencing breast tenderness and lumps after three weeks on 0.5 mg oral finasteride, a common side effect. They also report mild brain fog and fatigue but are less concerned about these symptoms.

The user is experiencing severe hair thinning and is using multiple treatments including topical finasteride, minoxidil, tretinoin, latanoprost, oral minoxidil, dutasteride, saw palmetto, and derma wounding. They are considering adding RU58841 and are contemplating a hair transplant and exosomes due to frustration with current results.

The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.

Dutasteride is more effective than finasteride, has neuroprotective benefits, and may prevent acne. Despite initial concerns about metabolic effects, further research suggests it is safe for most users, especially if not hypogonadal.

The conversation discusses skepticism and mixed opinions about a hair loss theory, mentioning treatments like Minoxidil, finasteride, RU58841, and Procyanidin B2. There is criticism of a content creator named HairCafe and the difficulty in obtaining effective sulforaphane supplements.

The user is considering switching to topical finasteride or pyrilutamide to stabilize hair loss before a hair transplant, currently using oral minoxidil and finasteride. Suggestions include sticking to the current regimen as it is already potent, and caution against using pyrilutamide from unreliable sources.

The conversation is about whether it is safe to take Xeljanz, a JAK inhibitor, while also taking finasteride for hair loss. The concern is that Xeljanz weakens the immune system, which could be risky.

The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.

The conversation discusses hair loss treatments, focusing on insulin resistance, microneedling with topical melatonin, and stress reduction. Users express skepticism about the advice, preferring proven treatments like minoxidil and finasteride, while some mention alternative methods like dermal incisions and verteporfin for reducing fibrosis.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

The conversation discusses that dutasteride may be more effective than finasteride for frontal hair loss due to higher 5ar Type 1 enzyme activity in that area. Some users question the validity of this information, while others confirm it with additional sources.

Low estrogen levels may reduce the risk of side effects from finasteride, such as gynecomastia. Some users plan to start with microneedling and minoxidil before trying finasteride, while others have experienced temporary side effects from topical finasteride but continued use without persistent issues.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The conversation discusses using tretinoin for hair loss and whether applying SPF on the scalp is necessary if hair covers the treated areas. The user is considering this treatment despite having no completely bald patches.

The conversation discusses a hair loss treatment regimen involving dutasteride, pyrilutamide, oral minoxidil, and microneedling, with the aim of suppressing DHT and stimulating hair growth. Users debate the effectiveness and potential side effects of these treatments, noting that individual results may vary and that no treatment is foolproof.

The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.

The user is experiencing hair loss and has been using RU58841 but is considering pyrilutamide and minoxidil, avoiding finasteride due to side effects. Another user suggests finasteride or dutasteride as essential, possibly in topical form, while dismissing saw palmetto as ineffective.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

Ultrasound imaging can non-invasively detect active and inactive hair follicles, inflammation, and fibrosis, potentially reducing unnecessary biopsies. It may help assess hair growth potential and diagnose scalp issues, but some users believe in trying treatments regardless of ultrasound results.

Combining minoxidil 5%, tazarotene 0.1% cream, and lumigan for hair loss treatment is discussed. The conversation focuses on the safety and effectiveness of using these treatments together.